← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Selexys Pharmaceuticals Corporation
Oklahoma City, OK
$10,013,587
Total funding
4
Grants
Funding over time
peak $2.7M · FY2009–16$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$8,908,192 · 3
FDA$1,105,395 · 1
By mechanism
R44$8,603,349 · 2
R01$1,105,395 · 1
R43$304,843 · 1
Investigators at Selexys Pharmaceuticals Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$2,091,208
R44 · FY2010 · HL
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease$1,276,671
R44 · FY2011 · DK
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,251,579
R44 · FY2009 · HL
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,037,638
R44 · FY2013 · HL
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,037,638
R44 · FY2014 · HL
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,037,638
R44 · FY2012 · HL
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease$560,627
R44 · FY2010 · DK
Phase 2 Study of SelG1 for the Treatment of Sickle Cell Disease$400,000
R01 · FY2015 · FD
Phase 2 Study of SelG1 for the Treatment of Sickle Cell Disease$364,000
R01 · FY2016 · FD
Phase 2 Study of SelG1 for the Treatment of Sickle Cell Disease$341,395
R01 · FY2014 · FD
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease$310,350
R44 · FY2014 · DK
PEGylation of a Glycosulfopeptide Anti-Inflammatory$304,843
R43 · FY2004 · HL